CHARACTERISTIC | Â |
---|---|
Age: Median (range) | 61years (46–74 years) |
Male | 26 (58%) |
Female | 19 (42%) |
Significant Bone disease1 | 23 (51%) |
Time following completion of treatment | 11months (median) |
 | (range 3–149 months) |
Previous ASCT2 | 42 (93%) |
Previous orthopaedic surgery | 6 (13%) |
Current therapies | Â |
Maintenance treatment | 9 (20%) |
• Lenalidomide | 1 |
• Interferon | 2 |
• Thalidomide | 6 |
Regular analgesia | 11 (24%) |